SU1801009A3 - Method of chronic prostatitis and prostate adenoma of the 1-st stage treatment - Google Patents

Description

The present invention relates to medicine, namely to urology and apitherapy and is intended for the treatment of diseases of the prostate gland.

The subject of the invention is a method for treating diseases of the prostate gland (chronic prostatitis and prostate adenoma), including the use of plant pollen obtained by bees as a therapeutic agent. Thus, the presented work relates to both urology and apitherapy.

Known methods of treating prostate diseases based on the use of preparations containing plant pollen. The drug Vitalprostat-diets manufactured by Erwin Hagen (Germany) contains active substances of pumpkin seeds and pumpkin pollen, characterized by increased biological effectiveness of Vitalprostat-diets - a granular product from pumpkin seeds and pollen contributes to the regression of benign prostate diseases. The pollen of many plants in combination with other beekeeping products (honey, propolis, royal jelly) contains the drug Mipropol. Methods of treating prostate diseases based on the use of these drugs have become widespread among specialists in epitherapy.

The closest in technical essence and effectiveness of treatment of prostate diseases * is a method based on the use of the drug Zernilton (Sweden), adopted as a prototype of the claimed technical solution. Zernilton? is a pollen extract of eight species of plants growing in southern Sweden, does not contain other biologically (/) C

1801009 AZ of active ingredients other than pollen / Therapeutic agent for diseases of the prostate gland - Cernilton tablets, informative manual survey, Engelholm, Sweden, 1976, 13 pages /. The prototype is inferior in clinical efficacy to the proposed method for the treatment of inflammatory diseases and prostatic hypertrophy.

The starting point for the creation of the proposed method was the work of Alain Kayyas Pollen - collection, properties, application, in which it was assumed that it was the pollen of a tree-brew that has a beneficial effect in prostatitis.

Tree heather is a relic plant and has only two limited ranges on Earth, one of which is located in the south of France (French Mediterranean). In the area of the French Mediterranean, it is impossible to obtain pollen of this plant in its pure form, since other plants bloom during the flowering of tree-like heather.

The only area of tree-heather in our country is in the Müsser reserve on the slopes of the Kavaklus Upland in the Abkhaz ASSR. The flowering period of tree heather here begins from February to March. At this time, other plants do not bloom in the Müsser Nature Reserve, therefore heather pollen is collected using bees in almost pure form, i.e. get monoflora pollen.

The aim of the proposed invention is to increase the efficiency of the method of conservative treatment of inflammatory diseases and hypertrophy of the prostate gland. The goal is achieved on the basis of a scientific approach to the use of natural conditions, i.e. the possibility of obtaining monoflore pollen of tree-heather in the Mussser Nature Reserve and the creation on its basis of a highly effective therapeutic agent. The method is as follows: pollen of heather flowers is collected using a pollen trap installed near the bee hive during the flowering period (February-March); the dosage form is made by mixing crushed pollen and cocoa butter, then preparing rectal suppositories from the resulting mixture; suppositories are administered to patients with prostate diseases (stage I prostate adenoma, chronic prostatitis) in the rectum and a course of treatment with the drug is carried out. Thus, the proposed method has a common feature with a prototype based on the use of Zernilton - both methods are based on the use of plant pollen, however, have a number of distinguishing features. In the present method, one type of pollen is used, which has the most pronounced effect on the function of the prostate gland, a method based on the use of Zernilton includes treatment with 8 species of plant pollen; in addition, the claimed method uses a more convenient dosage form for the treatment of these nosologies rectal suppositories, while Cernilton has an oral tablet form.

Cocoa butter, used as the basis for the preparation of candles provides a quick and complete release of the drug substance in the rectum. Biologically active substances of pollen enter the blood through the mucosa of the rectum and immediately reach the prostate gland. On the contrary, when implementing the basic method, the active pollen components contained in Zernilton, of course, change under the influence of gastric enzymes and acidic medium, change the specific structure and only after that reach the tissue of the prostate gland.

Example. 1.0 part (by weight) of heather pollen is mixed with 1.5 parts of cocoa butter, rectal suppositories are prepared from the resulting mixture and a course of treatment for patients with inflammatory and hypertrophic changes in the prostate lasting up to 30 days, 1 suppository 3 times a day.

The positive effect of the proposed method of treatment is shown in comparison with the therapeutic efficacy of the method based on the use of Zernilton (Sweden). Clinical observations were carried out for several years on volunteers suffering from chronic prostatitis (72 people) and volunteers suffering from prostate adenoma (73 people). Of the group of volunteers with chronic prostatitis, 44 patients underwent a course of treatment with suppositories containing Erica arborea pollen lasting 1 month. 28 people received a course of treatment of the same duration with Zernilton. The method of treatment with Zernilton is carried out according to the recommendations of the company, starting with 6 tablets per day, taken immediately after breakfast. After 5 days of treatment, the daily dose of the drug was reduced to 3-4 tablets (once). Positive results in the treatment of chronic forms of prostatitis by the claimed method were obtained in the vast majority of patients: 42 patients, while 32 people had a full recovery, 5 people had a significant improvement. Improvement in a number of clinical indicators was also detected in 5 patients, and only in 2 patients did the drug treatment fail to produce effect (Table 1). According to the table. 1 shows that the method of treatment of resistant chronic prostatitis with rectal suppositories containing pollen of heather tree, significantly exceeded the effectiveness of the method in which derivatives of 8 species of pollen were used as a therapeutic agent.

contained in cerniltone (half of the patients showed improvement in a number of clinical signs). The end result of treatment presented in the table was characterized by the following clinical signs: In patients who received rectal suppositories according to the claimed method, pain passed faster, resorption of inflammatory infiltrates in the prostate gland was observed (determined by palpation). In addition, measurements in the secretion of the prostate, whose composition was restored in the overwhelming majority of patients, disappeared.

In the treatment of stage I prostate adenoma, 49 volunteers received treatment according to the claimed method and 30 patients received treatment according to the prototype method. After a course of treatment with suppositories containing tree heather pollen, 80% of volunteers showed an improvement in their general condition and a decrease in the frequency of urination, 34 of 49 patients showed a decrease in neuropsychiatric disorders, 31 patients showed a decrease in prostate gland palpation, and a picture of white blood normalized in 14 people. (in particular lymphocytes), and in 15 people there was a significant improvement in blood picture 5.

According to table 2, which presents the final results of the course of treatment of prostate adenoma, it can be seen that when using the claimed 10 method, significant clinical improvement (in terms of the dynamics of the above symptoms) was observed in a larger percentage of cases than during treatment with cernilton.

Thus, conservative treatment with rectal suppositories containing pollen from tree heather in patients with stage I prostate adenoma helps to reduce the severity of 20 symptoms of the disease. In patients with chronic prostatitis, the claimed method is an effective method of treating the disease.

In table 3-10, attached to the text 25 of the description, the actual material on the dynamics of clinical symptoms and laboratory parameters is presented. In the treatment of diseases by the present method and prototype.

Claims (2)

30 Claims of the invention A method for the treatment of chronic prostatitis and stage I prostate adenoma, including the introduction of plant pollen, characterized in that, in order to reduce 35 treatment periods, rectal suppositories containing monoflora pollen from tree heather and cocoa butter in a ratio of 1: 1 are used, 5, which are administered 1 candle 3 times a day for 30 days. Table 1. Total patients. Recovery. Significant improvement. Improvement. Treatment without effect. The first group of volunteers (treatment according to the claimed method) 44 32 5 5 2 The second group of patients (treatment with cernilton) 28 - - 14 14. 7 Table 2 Total patients. Significant improvement. Improvement. Treatment without effect. The first group of volunteers (treatment according to the claimed method) 49 39 9 1 The second group of patients (treatment with Zernilton) 30 17 12 1 Table 3 No. of patients Symptoms of the disease Chronic prostatitis The proposed method The prototype before treatment after treatment before treatment after treatment η P m η P m η P m η p m 1 Pain 9 20 1.8 2 4.5 0.5 6 21 0.7 3 '11 0.5 2 Pain syndrome and dysuric phenomena 9 20 1.8 2 4.5 0.6 7 25 0.9 3 11 0.3 3 Pain, radiculitis, neuralgia 11 25 1.9 3 6.8 0.3 6 21 1.0 3 11 0 , 7. 4 Pain and impaired sexual function 10 23 1.4 3 6.8 0.7 7 25 1.1 4 14 0.2 5 Neurological disorders 5 12 1.1 2 4.5 0.5 2 8 0.6 1 3.6 0.2 Total: 44 100 12 27.1 28 100 14 50.6 Note. 1, η, ρ, πτ - see table H 1. η - the number of patients with the specified symptom p -% of the total number of patients in the hl group - standard error 2. According to the claimed method, the column after treatment shows the number of patients for whom pathological symptoms persisted partially (only 12 people). Of these, 5 people. the subjective state (according to the severity of the symptom) could be considered as a significant improvement, in 5 people. - as an improvement in 2 people. - no improvement. Recovery was achieved in 32 people. 3. According to the prototype - in the column - after treatment, the number of patients whose treatment did not give an effect is shown (total 14 people). In other cases, the condition was regarded as a significant improvement and improvement. Ta bl and q a4 No. p / p Symptoms of the disease Stage 1 prostate adenoma The claimed method Prototype before treatment after treatment before treatment after treatment η R m P R m η Ρ m η .....R...... m - 1 Pain 12 24.4 1,2 - - - 8 26.7 0.9 3 10.0 0.3 2 Pain syndrome rum and dysuric phenomena 12 24.4 1,2 2 4.0 0.3 9 30,0 0.8 3 10.0 0.3 3 Pain, sciatica, neuralgia 10 20,4 1.4 3 6.1 0.5 3 10.0 0.7 1 3.3 0.1 4 Pain and Violation sexual function 10 20.4 1.6 3 6.1 0.5 7 23.3 0.8 4 13.3 0.3 5 Neurological disorders 5 10,4 1,5 1 2.0 0.5 3 10.0 0.4 2 6.7 0.2 Total: 49 100 9 18.2 thirty 100 thirteen 43.3 Note. 2. According to the claimed method and prototype, the number of patients is shown in the graph after treatment for whom the condition has improved insignificantly and for whom the treatment had no effect (for T patient in each group - see table 2). Significant improvement in these signs occurred in 39 patients with treatment according to the claimed method (80%) and in 17 patients according to the prototype (56.7%). Table5 Gf Indicators of cro Chronic prostatitis p / p IN AND The proposed method Prototype before treatment after treatment BEFORE treatment after treatment η R m η R m P R m η R m 1 Increased leukocytosis 4 9.1 2.2 - - - 3 10.7 4.3 2 7.1 3.9 2 Increased content of segmented neutrophils (from 65 to 80%) 2 4,5 1.7 1 3.6 2,8 1 3.6 2.0 3 Increase ESR (over 10 μμΈ hour) 8 18.2 1,1 2 4.5 1,5 6 21,4 5.9 5 17.9 5.5 4 Total patients with changes in some blood parameters 14 31.8 3.8 2 4,5 1,5 10 35.7 6.9 8 28.6 6.6 Continuation of the table. 5 Ns s / n Blood counts Chronic prostatitis The proposed method Prototype before treatment after treatment before treatment after treatment η Ρ m η R m η Ρ m η R m 5 Total patients with normal blood counts thirty 68,2 3.8 42 95.5 1,5 18 64.3 6.9 20 71,4 6.6 Total patients 44 44 28 28 Tabl and Tsab Gf Indicators of cro Stage I prostate adenoma p / p IN AND The proposed method Prototype before treatment after treatment BEFORE treatment after treatment η R m . η R m η R m η R m 1 Increased leukocytosis 14 28.6 2,3 3 6.1 1.8 18 60.0 3.1 14 46.7 3.0 2 Increased content of segmented neutrophils (from 65 to 80%) 10 20,4 2,8 2 4.1 1.7 8 26.7 3.2 5 16.7 2.7 3 Increased ESR (s above 10 mm per hour) 29th 59.2 2.1 eleven 22.4 2,3 21 70.0 3,5 19 63.3 3.9 4 Total patients with changes in some blood parameters 37 75.5 2,5 10 20.5 2.0 23 76.7 2.7 20 66.7 3.4 5 Total patients with normal blood counts 12 24.5 2,5 39 79.5 2.0 7 23.3 2.7 10 33.3 3.4 Total patients 49 49 thirty thirty Table7 Ns s / n Nature of change BEFORE Chronic prostatitis The proposed method Prototype treatment after treatment BEFORE treatment after treatment η R hl η R m η Ρ m η R m 1 Norm 20 45.5 2.1 38 86.4 3.0 thirteen 46,4 2.4 19 67.9 2.3 2 Leukocyturia 22 50.0 2.5 6 13.6 2.9 thirteen 46,4 2.4 9 32.1 3.3 3 Erythrocyturia 1 2.25 1.3 1 3.6 1.3 Continuation of the table. 7 No. p / p Nature of change Chronic prostatitis The proposed method Prototype before treatment after treatment before treatment after treatment P R m η R m η m η R m 4 Leukocyturia'i and erythrocyturia 1 2.25 1.8 -. - - 1 3.6 - - - Total patients 44 44 28 28 Table 8 kfe p / p Nature of change Stage I prostate adenoma The proposed method Prototype before treatment after treatment before treatment after treatment η R m η R m η R m η " R...... m 1 Norm 8 16.3 2.2 36 73.5 2,3 6 20,0 2.4. thirteen 43.3 3.0 2 Leukocyturia 25 51.0 2,4 9 18,4 1.9 14 46.6 2.7 10 33.3 2.7. 3 Erythrocyturia 7 14.3 2.1 1 2.0 1.4 2 6.7 2.0 1 3.4 1.7 4 Leukocyturia and erythrocyturia 9 18.4 2.2 3 6.1 1.4 8 26.7 2,3 6 20.0 2.7 Total patients 49 49 thirty thirty TableE No. p / p Prostate Secret Indicators Chronic prostatitis The proposed method Prototype before treatment after treatment before treatment after treatment η R m η R ΠΊ η R m η Fri 1 The content of leukocytes in the field of view -DO 12 2 4,5 0.7 2 4,5 1.7 1 Ζ 3.6 1,6 3 10.7 1,5 -13-50 eleven 25.0 1.3 28 63.6 2.3 8 28.6 1.4 eleven 39.3 1.9 -51-100 18 41.0 1.5 12 27.4 2.0 12 42.8 1.6 9 32.1 0.8 - more than 100 thirteen 29.5 1,6 2 4,5 0.8 0.8 25.0 2.1 5 17.9 0.4 2 The content of lipoid grains in the field of view is a lot 3 6.8 0.9 1 3.6 0.7 2 7.2 1.6 Continuation of the table. 9 No. p / p Prostate Secret Indicators Chronic prostatitis The proposed method Prototype before treatment after treatment before treatment after treatment η R m η R gp η - £ - gp η R m - moderate amount 1.2 27,2 1.5 27 61,4 8 28.6 1,1 9 32.1 2,3 - insignificant amount 21 47.7 1.4 thirteen 29.5 thirteen 46,4 1.8 thirteen 46,4 2.7 - are absent 8 18.3 1,1 4 9.1 * 6 21,4 1.4 4 14.3 1.8 Total patients 44 44 28 28 Table 10 Nosological form Anatomical changes in palpation of the prostate gland The proposed method Prototype Identified Not identified Identified Not identified η R about R η R η R Chronic prostatitis 36 82.0 8 18.2 14 50,0 14 50.0. BPH 1 stage 42 85.7 7 14.3 17 56.7 thirteen 43.3